[ad_1]
hapabapa/iStock Editorial via Getty Images
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded.
In a Citizen Petition posted on Regulations.gov, Novo Nordisk (NVO) noted
[ad_2]
[ad_1] NioCorp Developments reports preliminary net loss of $0.5 million [ad_2]
[ad_1] Citius Pharmaceuticals GAAP EPS of -$5.97 [ad_2]
[ad_1] Radius Recycling Non-GAAP EPS of -$1.33 misses by $1.01, revenue of $657M misses by $17.7M [ad_2]
[ad_1] Sanctions? Russia is now using bitcoin for international trade [ad_2]
[ad_1] Obesity drug developer Metsera files for $100M IPO [ad_2]
[ad_1] Google scraps AI add-on fee, now includes AI features for free in Workspace plans [ad_2]